Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifepristone as salvage therapy in advanced NSCLC
NCT02642939Phase 2Terminated
- Start
- Dec 2015
- Primary completion
- Oct 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mifepristone in non-small cell lung cancer (NSCLC). Primary endpoints: Overall Survival at 16 months and Quality of Life at 56 months. Started Dec 2015; status: terminated.
02
Drugs
mifepristone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02642939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02642939.